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1Abstract
With the availability of genetic pathways or networks and accumulating knowledge
on genes with variants predisposing to diseases (disease genes), we propose a disease-
gene-centric support vector machine (DGC-SVM) that directly incorporates these
two sources of prior information into building microarray-based classiﬁers for binary
classiﬁcation problems. DGC-SVM aims to detect the genes clustering together and
around some key disease genes in a gene network. To achieve this goal, we propose a
penalty over suitably deﬁned groups of genes. A hierarchy is imposed on an undirected
gene network to facilitate the deﬁnition of such gene groups. Our proposed DGC-
SVM utilizes the hinge loss penalized by a sum of the L∞-norm being applied to
each group. The simulation studies show that DGC-SVM not only detects more
disease genes along pathways than the existing standard SVM and SVM with an L1-
penalty (L1-SVM), but also captures disease genes that potentially aﬀect the outcome
only weakly. Two real data applications demonstrate that DGC-SVM improves gene
selection with predictive performance comparable to the standard-SVM and L1-SVM.
The proposed method has the potential to be an eﬀective classiﬁcation tool that
encourages gene selection along paths to or clustering around known disease genes
for microarray data.
Key Word: DAG; Gene expression; Gene network; Grouped penalty; Hierarchy;
Penalization.
21 Introduction
Genes interact with each other through their RNA and protein expression products.
For example, the rate at which transcription factor genes are transcribed into RNA
molecules may govern the transcriptional rate of their regulatory target genes, which
as a result become either up- or down- regulated. A gene network is a collection of
eﬀective interactions, describing the multiple ways through which one gene aﬀects all
the others to which it is connected. A gene network reveals genetic dynamics under-
lying the aggregate function that the network maintains. High-throughput genomic
advances have generated various databases providing gene network information, such
as the Biomolecular Interaction Network Database (BIND) (Alfarano et al 2005), the
Human Protein Reference Database (HPRD) (Peri et al 2004), and the Kyoto En-
cyclopedia of Genes and Genomes (KEGG) (Kanehisa et al 2004). In recent years,
genetic studies have uncovered hundreds of genes with variants that predispose to
common diseases, such as cancer, Parkinson’s disease, and diabetes. For example,
gene TP53 is among the most famous ones, which, as a tumor suppressor, is central to
many anti-cancer mechanisms. Gene TP53 encodes tumor protein p53, the so-called
”the guardian of the genome”, which mediates cellular response to DNA damage and
is involved in other important biological processes, e.g., cell cycle. Among its other
functions, p53 activates other genes to ﬁx the damage if p53 determines that the
DNA can be repaired. Otherwise, p53 prevents the cell from dividing and signals its
death. Most mutations that deactivate TP53 destroy protein p53’s ability to reg-
ulate other genes properly and thus leads to increasing risk of tumor development
(Soussi and B´ eroud 2003; Børresen-Dale 2003). Hence, not just a single gene, but a
subnetwork of TP53 and its interacting partners, are involved in the disease process.
With the availability of various repositories of gene networks and the accumulating
knowledge on genes linked to diseases, one question naturally arises: how to integrate
the two sources of prior information into a model to detect genes involved in disease-
3related biological processes. A network-based approach takes such a coherent view
and makes use of the network information in building statistical models. Employ-
ing a network-based perspective not only sheds insight within the network modules
(Calvano et al 2005; Benson 2006; Chuang et al 2007; Liu et al 2007) but also al-
lows the possibility to identify disease genes that have only weak eﬀects. Such genes
often play a central role in discriminative subnetworks by interconnecting groups
of genes involved in various biological processes. Chuang et al (2007) pointed out
that several well-known cancer genes, such as TP53, KRAS, and HRAS, were ig-
nored by gene-expression-alone analysis but successfully detected by using network
information. However, their network-based approach involves a random search over
subnetworks, leading to possibly instable and suboptimal ﬁnal results.
Since its invention (Vapnik 1995; Cortes and Vapnik 1995), the support vector
machine (SVM) has been acclaimed as a useful regularization method due to its ex-
cellent empirical performance, especially with high dimensional data (Brown et al
2000; Furey et al 2000), its possible extensions to accommodate various penalty func-
tions, and resulting model sparsity if a suitable penalty (e.g. L1-norm) is employed.
For binary classiﬁcation, the standard L2-norm SVM (STD-SVM) has good predic-
tive performance, but is incapable of performing variable selection. The L1-SVM
(Zhu et al 2003; Wang and Shen 2007) produces sparse models for data with p >> n.
Zou and Yuan (2008) developed a grouped variable selection scheme for factors by
the use of an F∞-norm SVM such that all features derived from the same factor
(i.e. categorical predictor) are included or excluded simultaneously. Note that their
grouping scheme was based on non-overlapping groups. Zhao et al (to appear) gen-
eralized grouped variable selection and introduced the composite absolute penalties
(CAP) family. CAP achieves both grouped selection for non-overlapping groups and
hierarchical selection for overlapping groups. Extending the idea of grouping to gene
networks, Zhu et al (2009) proposed a network-based SVM (NG-SVM), treating any
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network information into building classiﬁers. Both the simulation studies and real
data applications showed that NG-SVM enjoyed advantages in gene selection and
predictive performance compared with the popular STD-SVM and L1-SVM. How-
ever, a potential problem of NG-SVM lies in its tendency of selecting isolated genes
or gene pairs, i.e., genes largely disconnected to each other in the network, which is
not desirable given that some disease genes cluster together and form subnetworks.
In this paper, we embed the information of both a gene network and some crucial
disease genes into the SVM framework by emploiting two ways of grouping genes to
construct penalties. By considering an undirected network to be anchored on certain
crucial disease gene(s), i.e., genes known to be central to a disease, a hierarchical
structure is imposed on the network (with the anchoring crucial genes at the top) to
facilitate the deﬁnition of various gene groups. By summing up an L∞-norm over each
group, we obtain the penalty for DGC-SVM. Ideally, by DGC-SVM, identiﬁcation of
one gene triggers the inclusion of the disease genes along the connected paths towards
the top crucial gene(s). In particular, we intend to capture disease genes, even if their
direct eﬀects on the outcome are weak, which are important in regulating functional
activities of other genes along the pathways or within the subnetworks involved in
the disease.
2 Methods
2.1 Orienting an undirected network
Starting from an undirected network G, we convert it into a directed acyclic graph
(DAG) ˜ G. Suppose that G originates from only one disease gene g and consists
of p genes in total. Genes (including g) in network G are indexed by {1,2,...,p}.
We have the expression levels of the p genes and a binary outcome for N samples,
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i=1 with xi ∈ Rp and yi ∈ {1,−1}. The expression of each gene is normalized
to have mean 0 and standard deviation 1 across samples. We deﬁne a directed edge
by an ordered pair of ends (a,b) indicating that a is upstream to b, or equivalently, b is
downstream to a. Since genetic interrelationships occur only between pairs of distinct
genes, network G contains no loop, deﬁned as a directed edge with identical ends.
In addition, no two directed edges adjoin the same pair of genes. Gene g is the top
(center) gene of network G. The distance between two genes a and b is the minimum
number of directed edges traversed from a to b. Genes closer to the network origin,
gene g, are said to be at an upper level than those farther apart. Genes with the same
distance from the origin are at the same level. For example, the distance between
gene g and any of its direct neighbors is 1. The distance between any two genes at the
same level is 0. Thus, DAG ˜ G is deﬁned from the undirected network G. ˜ G assigns
directions from upper-level to lower-level genes but ignores edges connecting genes at
the same level. Upper-level genes are called nodes whereas genes with no downstream
genes are named as leaves. DAG ˜ G captures the upper-lower interrelationships but
ignoring the lateral ones.
If we have more than one center genes g1 ...gL, DAG ˜ G can be deﬁned as follows:
(1) Derive DAGs ˜ G1 ... ˜ GL, each corresponding to one center gene in g1 ...gL; (2)
˜ G = ∪L
l=1 ˜ Gl if ˜ G1 ... ˜ GL share no common nodes; (3) if the DAGs have common
nodes, pick up any of them, align all the associated DAGs at the level where that
common node is seated, treat that node in each associated DAG as being located
at the same level (named as levelv), and merge the associated DAGs by recognizing
only the upper-lower interrelationships but ignoring the lateral ones. Then, identify
the common nodes of the merged DAG and the remaining untouched DAGs, repeat
step (3) until no common nodes exist. Note that each node in the merged DAG has
the same downstream genes no matter which center the node is derived from. The
above process may result in diﬀerent DAGs if the combination of the associated DAGs
6occurs at diﬀerent common nodes, introducing certain arbitrariness.
2.2 Pathway grouping
To achieve our goal of detecting collectives of genes involved in disease along pathways
or within subnetworks, we form a penalty on suitably deﬁned groups of genes. We
experiment two ways of grouping: (linear) pathway (PW) grouping and partial tree
(PT) grouping. We ﬁrst describe the PW grouping. It forms groups along linear
paths as an attempt to encourage (linear) pathway selection.
A path in ˜ G is a connected sequence of directed edges and the length of the path is
the number of directed edges traversed. Note that a path connects genes from upper-
to lower-levels without any two consecutive genes from the same level. Since a path
can be determined by the sequence of the nodes the path, a path is simply speciﬁed
by its node sequence. We deﬁne a single node as a trivial path. Deﬁne a complete
path of leaf k in ˜ G, Ek (k = 1,...,K), as
Ek = {j : Gene j appears on the path from the top gene g down to leaf k}.
Suppose Ek contains a total of nk genes, including leaf k and gene g. Then we have
nk groups with a hierarchical structure G
(k)
t (t = 1,...,nk) by grouping the genes
in Ek under the ”lower nested within upper” rule, that is, node/leaf at a lower level
must appear in all the groups that contain any node at an upper-level. For example,
in the network displayed in Figure 1, if gene 1 is considered to be at the top, then
genes 1,...,12 are nodes and genes 13,...,26 are leaves. The complete path of leaf
gene 16, E16, is {1,2,6,16}. Hierarchical groups derived from E16 or leaf gene 16 are
{2,6,16}, {6,16}, {16}, and E16 itself. Note that multiple distinct complete paths
may exist between leaf k and gene g, for example, {g,a,c,k} and {g,b,c,k}. In this
case, group {c,k} and group {k} are deﬁned twice respectively. When forming groups,
we count each distinct group only once. Therefore, groups formed from {g,a,c,k}
7and {g,b,c,k} include 6 groups: {g,a,c,k}, {g,b,c,k}, {a,c,k}, {b,c,k}, {c,k}, and
{k}. Thus, we impose a grouping structure G containing distinct groups on ˜ G, that
is, every group in G appears only once:
G = (G
(1)
1 ,...,G
(1)
n1 ,...,G
(K)
1 ,...,G
(K)
nK ),
while a gene may appear in multiple groups, which causes no problem in the below
formulation and computation.
Corresponding to G, we construct our penalty as
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The hinge loss penalized by (1) leads to our proposed DGC-SVM with PW grouping
(DGC-SVM-PW), which is developed as an attempt to encourage selecting genes
along the pathway (pathway selection).
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where the subscript ”+” denotes the positive part, i.e., z+ = max{z,0}, λ is the
tuning parameter, and  βG
(k)
t  ∞ = maxs∈G
(k)
t {|βs|/ws} with ws as a weight for gene
s. For example, we can deﬁne ws =
√
ds with ds as the number of direct neighbors of
gene s, or ws = ds, or simply ws = 1 for all genes. The solution to (2) can be found
as a linear programming problem:
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(k)
t = maxs∈G
(k)
t {|βs|/ws} and βs = β+
s −β−
s ,
in which β+
s and β−
s denote the positive and negative parts of βs. Note that, by our
construction, some genes fall within multiple groups G
(k)
t , which however causes no
computational problem with the above linear programming.
2.3 Partial tree grouping
The PT grouping is devised to achieve hierarchical selection, that is, the selection of a
lower-level gene ensures the selection of its upper-level gene(s). In addition, selecting
any gene in the DAG guarantees the inclusion of at least one center gene, which is
desirable in view of the biological importance of any center gene. The DGC-SVM
with PT grouping (DGC-SVM-PT) groups each node/leaf with all its downstream
genes. Since a leaf has no downstream genes, the group derived from the leaf contains
only one element, the leaf itself. For the above ˜ G, we have p groups in total, K of
which contain only single elements derived from K leaves, and the rest p−K of which
are formed as
Gq = {node q and all its downstream genes, q = 1,...,p − K}.
For example, the simple network in Figure 1 derives 26 groups, including (G1) that
contains all the 26 genes, and 14 single-leaf groups. Here we impose the grouping
structure as G = (G1,...,Gp). The formulation of DGC-SVM-PT is the same as its
PW grouping counterpart (2)-(4).
The DGC-SVM-PT is a direct application of the CAP family of Zhao et al (to ap-
pear) in the context of SVM. It enjoys the hierarchical property that if any node/leaf
at a lower-level is included in the model, the nodes at any upper-level in the group
will be almost surely included. This property is important to our goal of capturing
disease genes along pathways or within subnetworks, which oﬀers the possibility of de-
tecting genes that may have weak eﬀects but play a central role in regulating multiple
9biological processes through connecting various functional groups of disease-relevant
genes. In addition, this property guarantees the identiﬁcation of a center gene of the
network if any gene in the network is selected.
2.4 Choice of weight
DGC-SVM involves a weight function w. The choice of the weight depends on the
goal of shrinkage and governs variable selection and predictive performance.
A main motivation behind the proposed penalties is the grouping eﬀect of the L∞
norm. Because of the singularity of the penalty max(|a|,|b|) at |a| = |b|, by Fan and
Li (2001), the penalty encourages the shrinkage to |a| = |b|, which can be achieved
if the penalization parameter λ is large enough. For linear regression, this so-called
grouping eﬀect has been theoretically established by Bondell and Reich (2008) and
Pan et al (2009) for two-gene groups, and by Wu et al (2008) for a more general
case with more than two genes in a group. Now consider network G and its grouping
structure G derived from ˜ G. For simplicity, we assume that G contains only two-gene
and one-gene groups. For these two-gene groups, the weighted penalty encourages
|βj1|/wj1 = |βj2|/wj2 where βj1 and βj2 belong to the same group. Here we examine
three weight functions speciﬁcally: ws = 1, ws =
√
ds, and ws = ds, where ds is the
degree of gene s, i.e., the number of direct neighbors of gene s. The new method
encourages |βj1| = |βj2| if ws = 1,
|βj1| √
dj1
=
|βj2| √
dj2
if ws =
√
ds, and
|βj1|
dj1 =
|βj2|
dj2 if
ws = ds. The same reasoning also applies to groups with more than two genes.
Therefore, larger weights (from ws = 1, ws =
√
ds, to ws = ds) favor genes with more
direct neighbors to have larger coeﬃcient estimates; in other words, larger weights
relax the shrinkage eﬀect for those ”hub” genes that are connected to many genes
and are known to be biologically more important. Due to this property, the choice of
a large weight, as a simple strategy, enables us to alleviate the bias in the coeﬃcient
estimates from penalization and possibly improve predictive performance. The weight
10can be considered as a tuning parameter and determined by cross-validation or an
independent tuning data set, though we will not pursue it here.
Since the proposed penalty is linear, linear programming can be used to solve the
resulting optimization problem. We implemented the method by R package lpsolve.
3 Simulation
We numerically evaluated the new methods, DGC-SVM-PW and DGC-SVM-PT, in
two simulation studies over a simple network and a more complex one. The DAG for
a simple network is essentially a hierarchical tree where any two genes are connected
by a unique path. In contrast, there exist multiple paths adjoining the same pair of
genes in the complicated network. The grouping structure in either case is unique.
We compare the performance of DGC-SVMs with that of STD-SVM, L1-SVM, and
NG-SVM. The R package e1071 (with linear kernel) was used to obtain the solutions
of the STD-SVM, while the other ones were implemented by the R package lpsolve.
3.1 A simple network
We applied the DGC-SVM to the simple network depicted in Figure 1. Any two genes
in its DAG are connected by a unique path. The simulation data sets were generated
following the set-ups of Li and Li (2008).
• Generate the expression level of center gene 1, X1 ∼ N(0,1).
• Assume node s and each of its downstream genes follow a bivariate normal
distribution with means 0 and unit variances with correlation 0.7. Thus, the
expression level of each downstream gene is distributed as N(0.7Xs,0.51).
• Generate outcome Y from a logistic regression model: Logit(Pr(Y = 1|X)) =
XTβ + β0, β0 = 2, where X is a vector of the expression levels of all the genes,
11and β is the corresponding coeﬃcient vector.
We considered three sets of informative genes. The eﬀect of each informative gene
on the outcome was equal to that of its upstream node divided by the square-root
of the upstream node’s degree. All the other genes were noninformative, which had
no eﬀect on the outcome. Three sets of true coeﬃcients, β = (β1,β2,...,βi,...,β26),
were speciﬁed in three scenarios:
1. PT setting: one of the tree branches of the hierarchical tree or DAG (gene 1, 2,
5, 6, 14, 15, and 16) was informative.
β = (5,β1/
√
3,0,0,β2/
√
3,β2/
√
3,0,    ,0 | {z }
7
,β5/
√
2,β6/
√
3,β6/
√
3,0,    ,0 | {z }
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).
2. PW setting: pathway {1,3,7,17} was informative.
β = (5,0,β1/
√
3,0,0,0,β3/
√
4,0,    ,0 | {z }
9
,β7/
√
2,0,    ,0 | {z }
9
).
3. PW setting: pathway {1,2,5,14} was informative.
β = (5,β1/
√
3,0,0,β2/
√
3,0,    ,0 | {z }
8
,β5/
√
2,0,    ,0 | {z }
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).
In each scenario, we simulated 50, 50 and 10,000 observations for each training, tuning
and test dataset. For each of tuning parameter values, we obtained a classiﬁer from the
training data, applied it to the tuning data, and identiﬁed ˆ λ that yielded the minimal
classiﬁcation error over the tuning set. Then we used the classiﬁer corresponding to ˆ λ
to compute the classiﬁcation error on the test data. The entire process was repeated
100 times (i.e., 100 independent runs). The means of the test classiﬁcation errors,
false negatives (the number of informative genes whose coeﬃcients were estimated to
be zero), model sizes (the number of genes whose coeﬃcients were estimated to be
nonzero), and their corresponding standard errors (sd/
√
run) are reported in Table 1.
Evidently, DGC-SVM-PT generated models as sparse as that obtained from L1-
SVM, and gave the most accurate predictions among all the other methods. In addi-
tion, the center gene, gene 1, was detected in each run by DGC-SVM-PT. NG-SVM
12and DGC-SVM-PW yielded fewer false negatives due to the larger models produced
by each method. The weight w = d improved the classiﬁcation accuracy, slightly
shrank the model size, and kept almost the same false negatives for NG-SVM and
DGC-SVM-PW compared with the other two weight functions. In contrast, w = 1
worked better for DGC-SVM-PT. It reduced the false negatives while produced mod-
els of comparable predictive performance to that with w =
√
d or w = 1. Therefore,
DGC-SVM-PT with w = 1 was the winner. In addition, it also improved reproducibil-
ity. The most frequently-recovered pathways from each method (L1-SVM, NG-SVM
w =
√
d, DGC-SVM-PW w =
√
d, and DGC-SVM-PT w =
√
d) are displayed in
Figure 2. Both DGC-SVM-PT and L1-SVM missed the leaves under each scenario.
However, both identiﬁed the majority parts of the true pathways. Compared with
all the other methods, DGC-SVM-PT detected the same pathway in a much higher
frequency. Therefore, the identiﬁed pathways by this method were more reproducible.
3.2 A complicated network
Next, we explored the complicated network originating from gene 1 as displayed in
Figure 3. For this network, there exists one pair of genes that is connected by more
than one path. Therefore, the DAG derived from the complicated network is not a
tree. For example, gene 32 has both gene 23 and gene 3 at its upstream. In addition,
genes at the same level are connected, such as gene 22 and gene 23, and gene 33
and gene 34. By deﬁnition, genes with no downstream genes are considered as leaves.
Even though gene 22 is connected with gene 23, gene 22 is considered as a leaf because
gene 23 is at the same level as gene 22. Likewise, genes 33 and 34 are both treated
as leaves. Therefore, diﬀering from the simple network, the DAG deﬁned by the
complicated network contains directed edges characterizing upper-lower relationships
but ignores undirected edges describing lateral connections. Genes 1, 2, and 3 are
assumed to be disease genes that aﬀect the outcome weakly but importantly. Our
13goal is to identify disease genes, inlcuding those that play a critical role in mediating
other genes in multiple biological processes even if their direct eﬀects on the outcome
are weak.
The simulated data were generated similarly as for the simple network. Here, we
considered two scenarios: (1) genes 1, 2, and 3 had weak eﬀects (β1 = β2 = β3 = 0.1),
and leaf gene 32 had strong eﬀect (β32 = 10); (2) the three disease genes had the
same eﬀect as in scenario (1) whereas leaf gene 34 had strong eﬀect (β34 = 10).
Table 2 suggests that L1-SVM generated sparse models that gave the most accu-
rate predictions under both the scenarios. However, on average, it missed about 2.5
out of 4 informative genes and identiﬁed only around 0.5 out of 3 disease genes. In
contrast, NG-SVM yielded models that contained every gene. Even though DGC-
SVMs led to bigger test errors than L1-SVM, they detected most of the informative
and disease genes. In particular, DGC-SVM-PT detected all the informative and
disease genes. The diﬀerent weights led to similar results. Figure 4 displays the
pathways most frequently identiﬁed by each method (w =
√
d when a weight was
involved) except the standard SVM in each scenario. It is obvious that L1-SVM
most frequently captured the gene that exerted the largest inﬂuence on the response
(genes 32 and 34 in scenarios 1 and 2 respectively). NG-SVM included every gene
in each run, that is, it did not distinguish informative genes from the noise genes.
After examining the output closely, we ﬁnd that the DGC-SVM-PT selected all the
informative genes as well as all the three disease genes in each run even though the
three disease genes aﬀected the response weakly. Although this method generated
larger models and made less accurate predictions compared with L1-SVM, it exactly
realized our attempt to identify all the disease genes along a pathway, including those
with only weak eﬀects.
144 Applications to microarray data
To evaluate their performance in the real world, we applied the proposed DGC-SVMs
to two microarray data sets related to breast cancer metastasis (Wang et al 2005;
Chuang et al 2007) and Parkinson’s disease (Scherzer et al 2007) (Gene Expression
Omnibus: GSE6613; ttp://www.lncbi.nlm.ni.gov/geo/).
4.1 Breast cancer metastasis
The breast cancer metastasis (BC) data set contains expression levels of 8,141 genes
from 286 patients, 106 of whom developed metastasis within a 5-year follow-up after
surgery. The data set includes three tumor suppressor genes, TP53, BRCA1, and
BRCA2, which are known for preventing uncontrolled cell proliferation, and for play-
ing a critical role in repairing the chromosomal damage. The malfunction of these
genes leads to an increased risk of breast cancer. The protein-protein interaction
(PPI) network previously used by Chuang et al (2007) was adopted as our prior bio-
logical information, which was obtained by assembling a pooled data set comprising
57,235 interactions among 11,203 proteins and curation of the literature. We consid-
ered a subnetwork consisting of the direct neighbors of the three tumor suppressor
genes, denoted as BC-1nb-net. Eexpression levels of a total of 294 genes that belong
to BC-1nb-net were observed. In our analysis, due to its prominent role, TP53 was
considered as the center gene of the network.
In each run, we randomly split the data into training, tuning, and testing set
with 95, 95 and 96 observations respectively. The expression level of each gene was
normalized to have mean 0 and standard deviation 1 across samples. Given any
value from a prespeciﬁed set of wide-ranging values for the tuning parameter λ, we
obtained the classiﬁer ˆ fλ on the training set and applied ˆ fλ on tuning data. The value
of λ that yielded the minimal classiﬁcation error on the tuning data was chosen as
15ˆ λ. Then we applied the classiﬁer ˆ fˆ λ on the test set to evaluate its performance. We
compared the performance of DGC-SVM with that of STD-SVM, L1-SVM, and NG-
SVM in terms of classiﬁcation error, selection of mutant genes (genes with available
mutation frequencies), and model sparsity, averaged over 50 runs. Since genes with
large mutation frequencies are more likely to malfunction, disturbing the aggregate
activity of the network, a method that can detect more such mutant genes may be
considered to perform better. The mutation frequencies of 227 genes are available
(Chuang et al 2007). Among the 294 genes in BC-1nb-net were 40 genes with mutation
frequencies (named as cancer genes), 7 of which (ABL1, JAK2, p53, PTEN, p14ARF,
PTCH, and RB) with a mutation frequency larger than 0.10 (named as cancer genes
with large mutation frequency).
Table 3 indicates that all the methods had similar predictive accuracies even
though DGC-SVM-PT with w = 1 was slightly better. However, an improvement in
detecting clinically relevant genes was signiﬁcant by incorporating the prior network
information. Compared with L1-SVM, NG-SVM with w = d detected almost twice
as many frequently mutant cancer genes and more than 1.5 times cancer genes with
models less than 1.5 times larger. DGC-SVM-PW with w = d generated a more sparse
model with 3 genes less than L1-SVM while detected the same number of cancer genes
and almost twice as many frequently mutant cancer genes as L1-SVM. The advantage
of DGC-SVM-PT with w = d in gene selection was evident. It captured almost 3.5
times as many frequently mutant cancer genes and almost twice cancer genes by a
model only 1.2 times larger than L1-SVM. The proposed DGC-SVM prevailed the
other methods in identifying clinically important genes.
4.2 Parkinson’s Disease
The Parkinson’s disease (PD) data set includes disease status and expression levels
of 22,283 genes from 105 patients, 50 cases and 55 controls (Scherzer et al 2007). The
16gene network information was obtained from two sources: (1) the network in Li and Li
(2008), which combines 33 KEGG regulatory pathways and contains 1,523 genes and
6,865 edges; (2) the Parkinson’s disease KEGG pathway (PD-KEGG, ttp://www.
genome.ad.jp/kegg/patway/hsa/hsa05020.html), which uncovers the interactions
of 27 PD disease genes as of November 2008. A total of 12 out of the 27 PD disease
genes are contained in the network of Li and Li: UBB, UBE1, CASP9, CASP3,
APAF1, CYCS, PARK2, GPR37, SEPT5, SNCAIP, SNCA, and TH. We focused our
analysis on a subnetwork expanded from the 12 disease genes with the network of
Li and Li, denoted as PD-net (Figure 5), which consists of four components: (1) the
6th-order-neighbor-subnetwork of UBB (A direct neighbor of UBB is deﬁned as a
1st-order-neighbor; a direct neighbor of a 1st-order-neighbor of UBB as a 2nd-order-
neighbor; and so on.); (2) the 3rd-order-neighbor-subnetwork of CASP9; (3) the
isolated four-gene-subnetwork including PARK2, GPR37, SEPT5, and SNCAIP; and
(4) the isolated two-gene-subnetwork including SNCA and TH. A total of 181 genes
belong to PD-net. Note that PARK2/GPR37/SEPT5/SNCAIP and SNCA/TH
form two islands respectively. The DAG of PD-net (Figure 6) was obtained by merging
the DAG of UBB and that of CASP9 at the common node SMAD7. Note the two
islands in Figure 6.
In each run, the data set was randomly split into training, tuning, and test sets
with 40, 20, and 45 observations respectively. The expression level of each gene was
normalized to have mean 0 and standard deviation 1 across samples. The performance
of each method was evaluated on the test set by the classiﬁcation error, the selection
of PD genes, and model sparsity averaged over 50 runs. Again ﬁve methods were
compared: STD-SVM, L1-SVM, NG-SVM, DGC-SVM-PW (w = 1, w =
√
d, or
w = d), and DGC-SVM-PT (w = 1, w =
√
d, or w = d). To obtain the ﬁnal
model for each method, we used a new tuning dataset by combining, in each run,
the previous tuning and test data, leading to a sample size as large as 65. Here ˆ λ
17was identiﬁed on the new tuning set from a wide range of prespeciﬁed values. We
averaged the classiﬁcation errors corresponding to each tuning parameter value over
50 runs. The value ˆ λ leading to the minimal average error was used to ﬁt the ﬁnal
model to all the data. Note that the classiﬁcation error from the ﬁnal model was
likely to be biased due to reuse of the data for training/tuning and test; the purpose
of ﬁtting the ﬁnal model was to yield a set of selected genes.
As Table 4 indicates, the methods that incorporate the prior gene network infor-
mation improved gene selection while maintaining a predictive accuracy comparable
to that of the STD-SVM and L1-SVM. L1-SVM generated models with an average
of 16.86 genes including 1.50 PD genes. NG-SVM with w = 1 detected more than
twice as many PD genes with models having 1.28 less genes than L1-SVM. The im-
provement in gene selection of DGC-SVM-PW with w = 1 was more signiﬁcant. It
produced models with 3.76 less genes while detected more than three times as many
PD genes as L1-SVM. Both the methods had a predictive accuracy at a comparable
level to that of L1-SVM. DGC-SVM-PT with w = 1 improved both prediction accu-
racy and gene selection. It reduced the classiﬁcation error by 17% and also selected
three times as many PD genes with a model size not so much larger than that of
L1-SVM. Overall, DGC-SVM-PT with w = 1 outperformed the other methods.
The selected genes of the ﬁnal model obtained from each method (L1-SVM, NG-
SVM with w = 1, DGC-SVM-PW with w = 1, and DGC-SVM-PT with w = 1) are
displayed in the networks in Figure 7, Figure 8, Figure 9 and Figure 10. L1-SVM
generated the sparsest ﬁnal model and missed the most PD genes. NG-SVM selected
more leaves, some of which were from the two islands, while neglecting around a half
of the nodes. According to DGC-SVM-PT, nodes located at higher level are more
likely to have nonzero estimates. The majority of nodes were detected and some of the
genes from the two islands were included by this method. DGC-SVM-PW identiﬁed
the most PD genes among the four ﬁnal models, though it neglected most part of the
18subnetwork derived from UBB.
5 Discussion and conclusion
The availability of various repositories of gene networks and the accumulating knowl-
edge on genes central to diseases make it possible to use these two sources of prior
biological information to help build microarray-based classiﬁers. Employing such
a network-based perspective not only sheds insight on deciphering the complexity
within the network modules but also oﬀers the possibility to detect genes that play a
critical role in mediating multiple biological processes but have weak direct eﬀects on
the outcome by themselves. Such genes are often ignored by gene-expression-alone
analysis, as pointed out by Chuang et al (2007).
In this paper, we were motivated to devise a penalty that encourages gene selec-
tion along pathways or within subnetworks. The identiﬁcation of any gene triggers
the search for disease genes along gene pathways or within subnetworks all the way
toward genes central to the disease. The penalty boosts investigation of relationships
within collectives of genes that contain both the selected genes and the central genes.
By converting the undirected gene network into DAG, we imposed an upper-lower
hierarchy on the gene network depending on each gene’s distance to the assumed
network center, typically gene(s) central to the disease. The DAG facilitated the deﬁ-
nition of gene groups according to one of two diﬀerent ways of grouping, one based on
grouping genes along linear pathways, and a second on grouping genes with all their
downstream genes. The penalty term was constructed from the L∞-norm being ap-
plied to each group. Combined with the hinge loss, we obtained our proposed method:
DGC-SVM-PW and DGC-SVM-PT. The former attempts to realize selection along
linear pathways in the network. The latter ensures the selection of an upper-level
gene if any of its downstream genes is selected, thus realizing hierarchical selection.
Due to this property, genes that have more downstream genes and are closer to the
19center are very likely to be detected. In addition, selection of any gene guarantees
the inclusion of at least one central gene. According to the simulation studies, DGC-
SVM detected more disease genes even if they potentially aﬀected the outcome only
weakly. Two real data applications showed that the new method prevailed STD-SVM
and L1-SVM in capturing clinically relevant genes while making either more accurate
or comparable predictions on the outcome. We conclude that DGC-SVM has the
potential to be an eﬀective classiﬁcation tool for microarray data.
Even though its strength in improving gene selection has been established, DGC-
SVM has weaknesses in four aspects. First, speciﬁcation of the network center is
somewhat arbitrary. Specifying diﬀerent central gene(s) results in diﬀerent group
structures and thus diﬀerent penalties. Second, how to deﬁne DAG when more than
one center gene exist is worth debating. We suggested an approach that is admittedly
somewhat arbitrary. Third, the computational cost of DGC-SVM-PW is expensive
for a large network since a large number of groups are derived. Fourth, use of the
weights may improve gene selection but also reduce predictive accuracy or vice versa;
it is not guaranteed to better both at the same time. A further investigation may
focus on developing a simpler and more eﬀective way to incorporate a prior gene
network.
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Figure 1: Left: Simple network originating from gene 1. Right: DAG derived from
the simple network.
24Table 1: Simulation results (averaged over 100 runs) for a simple network with p = 26
genes. There were 7, 4 and 4 informative genes in the three scenarios respectively.
Scenario Method Test Error (SE) # False Negative (SE) Model Size (SE)
1 STD 0.129 (0.003) 0.00 (0.00) 26.00 (0.00)
L1 0.122 (0.003) 2.81 (0.14) 7.19 (0.36)
NG (w = 1) 0.145 (0.004) 0.26 (0.05) 14.73 (0.47)
NG (w =
√
d) 0.123 (0.004) 0.10 (0.04) 15.32 (0.50)
NG (w = d) 0.108 (0.003) 0.12 (0.05) 14.47 (0.56)
PW (w = 1) 0.152 (0.003) 0.84 (0.07) 15.57 (0.65)
PW (w =
√
d) 0.136 (0.003) 0.93 (0.08) 16.90 (0.61)
PW (w = d) 0.126 (0.003) 1.60 (0.13) 14.44 (0.61)
PT (w = 1) 0.107 (0.003) 1.94 (0.14) 9.42 (0.53)
PT (w =
√
d) 0.107 (0.004) 2.51 (0.13) 8.65 (0.53)
PT (w = d) 0.110 (0.004) 3.08 (0.13) 7.39 (0.44)
2 STD 0.147 (0.003) 0.00 (0.00) 26.00 (0.00)
L1 0.118 (0.004) 0.99 (0.07) 6.56 (0.33)
NG (w = 1) 0.162 (0.004) 0.16 (0.05) 17.83 (0.52)
NG (w =
√
d) 0.138 (0.003) 0.01 (0.01) 17.33 (0.52)
NG (w = d) 0.125 (0.003) 0.04 (0.02) 16.09 (0.57)
PW (w = 1) 0.174 (0.003) 0.32 (0.05) 18.93 (0.48)
PW (w =
√
d) 0.163 (0.003) 0.42 (0.06) 16.31 (0.48)
PW (w = d) 0.144 (0.003) 0.43 (0.06) 14.94 (0.47)
PT (w = 1) 0.111 (0.003) 0.72 (0.08) 7.74 (0.49)
PT (w =
√
d) 0.109 (0.003) 1.05 (0.08) 6.64 (0.52)
PT (w = d) 0.113 (0.003) 1.32 (0.07) 6.07 (0.40)
3 STD 0.143 (0.002) 0.00 (0.00) 26.00 (0.00)
L1 0.120 (0.003) 0.96 (0.07) 6.67 (0.34)
NG (w = 1) 0.149 (0.003) 0.09 (0.04) 16.04 (0.53)
NG (w =
√
d) 0.127 (0.003) 0.02 (0.01) 15.50 (0.51)
NG (w = d) 0.117 (0.003) 0.06 (0.03) 13.25 (0.52)
PW (w = 1) 0.165 (0.002) 0.33 (0.05) 17.98 (0.55)
PW (w =
√
d) 0.147 (0.003) 0.34 (0.05) 16.96 (0.49)
PW (w = d) 0.141 (0.003) 0.41 (0.06) 15.39 (0.51)
PT (w = 1) 0.106 (0.003) 0.59 (0.07) 8.07 (0.53)
PT (w =
√
d) 0.110 (0.003) 1.10 (0.08) 5.84 (0.34)
PT (w = d) 0.113 (0.003) 1.28 (0.07) 5.71 (0.27)
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Figure 2: Most frequently recovered pathways. Rows from top to bottom: L1-SVM,
NG-SVM, DGC-SVM-PW, and DGC-SVM-PT. Columns from left to right: scenario 1
(S1) {1,2,5,6,14,15,16}, scenario 2 (S2) {1,3,7,17}, and scenario 3 (S3) {1,2,5,14}.
Frequencies of the recovered pathways are included in parentheses.
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Figure 3: Left: A complicated network originating from gene 1. Right: DAG deﬁned
from the network.
27Table 2: Simulation results (averaged over 100 runs) for a complicated network with
p = 13 genes. There were 4 informative genes in each scenario.
Scenario Method Test Error (SE) # False Negative (SE) Model Size (SE) # Disease Genes (SE)
1 STD 0.131 (0.002) 0.00 (0.00) 13.00 (0.00) 3.00 (0.00)
L1 0.089 (0.003) 2.59 (0.07) 3.04 (0.25) 0.41 (0.07)
NG (w = 1) 0.214 (0.005) 0.00 (0.00) 13.00 (0.00) 3.00 (0.00)
NG (w =
√
d) 0.210 (0.004) 0.00 (0.00) 13.00 (0.00) 3.00 (0.00)
NG (w = d) 0.216 (0.005) 0.00 (0.00) 13.00 (0.00) 3.00 (0.00)
PW (w = 1) 0.109 (0.003) 1.10 (0.14) 9.58 (0.36) 1.90 (0.14)
PW (w =
√
d) 0.115 (0.003) 0.86 (0.12) 9.70 (0.34) 2.14 (0.12)
PW (w = d) 0.117 (0.003) 0.46 (0.09) 10.65 (0.25) 2.54 (0.09)
PT (w = 1) 0.146 (0.004) 0.00 (0.00) 10.79 (0.20) 3.00 (0.00)
PT (w =
√
d) 0.145 (0.004) 0.00 (0.00) 10.86 (0.18) 3.00 (0.00)
PT (w = d) 0.145 (0.004) 0.00 (0.00) 10.62 (0.18) 3.00 (0.00)
2 STD 0.137 (0.003) 0.00 (0.00) 13.00 (0.00) 3.00 (0.00)
L1 0.095 (0.003) 2.46 (0.08) 3.75 (0.29) 0.54 (0.08)
NG (w = 1) 0.217 (0.005) 0.00 (0.00) 13.00 (0.00) 3.00 (0.00)
NG (w =
√
d) 0.213 (0.004) 0.00 (0.00) 13.00 (0.00) 3.00 (0.00)
NG (w = d) 0.215 (0.004) 0.00 (0.00) 13.00 (0.00) 3.00 (0.00)
PW (w = 1) 0.101 (0.004) 2.12 (0.13) 5.52 (0.44) 0.88 (0.13)
PW (w =
√
d) 0.099 (0.003) 1.56 (0.14) 6.79 (0.44) 1.44 (0.14)
PW (w = d) 0.107 (0.004) 1.16 (0.13) 8.03 (0.40) 1.84 (0.13)
PT (w = 1) 0.151 (0.004) 0.00 (0.00) 9.62 (0.25) 3.00 (0.00)
PT (w =
√
d) 0.150 (0.004) 0.00 (0.00) 9.97 (0.23) 3.00 (0.00)
PT (w = d) 0.152 (0.005) 0.00 (0.00) 9.98 (0.22) 3.00 (0.00)
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Figure 4: Most frequently recovered pathways. Rows from top to bottom: L1-SVM,
NG-SVM, DGC-SVM-PW, and DGC-SVM-PT. Columns from left to right: scenario
1 (S1) {1,2,3,32}, and scenario 2 (S2) {1,2,3,34}. Frequencies of the recovered
pathways are included in parentheses.
29Table 3: Breast cancer metastasis data with 294 genes in BC-1nb-net including 40
cancer genes, and 7 cancer genes with mutation frequencies larger than 0.10: classiﬁ-
cation error, number of selected cancer genes (CA), number of selected cancer genes
with mutation frequencies larger than 0.10 (CA-LMF), number of selected genes, and
their standard errors (SE in parentheses) obtained by averaging over 50 runs.
Method Error (SE) # CA-LMF # CA # Genes
STD 0.396 (0.006) 7.00 (0.00) 40.00 (0.00) 294.00 (0.00)
L1 0.384 (0.007) 0.46 (0.10) 3.92 (0.46) 26.48 (3.01)
NG (w = 1) 0.385 (0.008) 0.58 (0.10) 3.82 (0.45) 29.38 (2.91)
NG (w =
√
d) 0.388 (0.006) 0.64 (0.11) 4.90 (0.60) 31.82 (2.95)
NG (w = d) 0.404 (0.006) 0.86 (0.11) 6.42 (0.58) 36.88 (2.45)
PW (w = 1) 0.380 (0.007) 0.78 (0.15) 4.86 (0.55) 42.32 (4.27)
PW (w =
√
d) 0.382 (0.006) 0.62 (0.12) 4.48 (0.62) 30.50 (3.64)
PW (w = d) 0.396 (0.006) 0.86 (0.12) 3.96 (0.49) 23.80 (2.89)
PT (w = 1) 0.373 (0.006) 1.76 (0.16) 14.90 (1.09) 88.18 (6.31)
PT (w =
√
d) 0.395 (0.006) 1.84 (0.18) 12.52 (0.61) 63.88 (2.12)
PT (w = d) 0.396 (0.005) 1.58 (0.16) 7.20 (0.60) 31.76 (2.64)
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Figure 5: PD-net: subnetworks grown from the 12 PD disease genes (UBB, UBE1,
CASP9, CASP3, APAF1, CYCS, PARK2, GPR37, SEPT5, SNCAIP, SNCA, and
TH); 181 genes in total. PD genes are in red.
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Figure 6: DAG transformed from PD-net: 12 PD disease genes (UBB, UBE1, CASP9,
CASP3, APAF1, CYCS, PARK2, GPR37, SEPT5, SNCAIP, SNCA, and TH); 181
genes in total. PD genes are in red.
32Table 4: Parkinson’s disease: classiﬁcation error, number of selected disease genes,
number of selected genes, and their standard errors (SE in parentheses) obtained by
averaging over 50 runs.
Method Error (SE) # Disease Genes # Genes
STD 0.448 (0.011) 12.00 (0.00) 181.00 (0.00)
L1 0.490 (0.008) 1.50 (0.19) 16.86 (1.58)
Final - 5 70
NG (w = 1) 0.500 (0.011) 3.32 (0.39) 15.58 (1.72)
Final - 8 83
NG (w =
√
d) 0.501 (0.009) 0.66 (0.19) 12.00 (1.34)
Final - 12 102
NG (w = d) 0.493 (0.008) 0.00 (0.00) 14.10 (1.44)
Final - 5 133
PW (w = 1) 0.481 (0.010) 4.80 (0.43) 13.10 (1.52)
Final - 9 97
PW (w =
√
d) 0.493 (0.009) 3.26 (0.41) 13.22 (1.70)
Final - 9 103
PW (w = d) 0.493 (0.007) 1.52 (0.28) 14.70 (1.88)
Final - 7 97
PT (w = 1) 0.407 (0.011) 4.56 (0.41) 42.34 (4.64)
Final - 6 108
PT (w =
√
d) 0.445 (0.013) 2.40 (0.18) 45.04 (3.80)
Final - 6 113
PT (w = d) 0.456 (0.011) 2.42 (0.15) 55.56 (4.08)
Final - 5 117
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Figure 7: L1-SVM ﬁnal model: selected PD genes (UBB, UBE1, CASP9, CASP3, and
SNCA) in red; missed PD genes (APAF1, CYCS, PARK2, GPR37, SEPT5, SNCAIP,
and TH) in green; other selected genes in yellow; unselected genes in white; 181 genes
in total.
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Figure 8: NG-SVM with w = 1 ﬁnal model: selected PD genes (UBB, UBE1, CASP9,
APAF1, CYCS, SEPT5, SNCA, and TH) in red; missed PD genes (CASP3, PARK2,
GPR37, and SNCAIP) in green; other selected genes in yellow; unselected genes in
white; 181 genes in total.
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Figure 9: DGC-SVM-PW with w = 1 ﬁnal model: selected PD genes (CASP9,
CASP3, SNCA, CYCS, APAF1, TH, PARK2, SEPT5, and SNCAIP) in red; missed
PD genes (UBB, UBE1, and GPR37,) in green; other selected genes in yellow; unse-
lected genes in white; 181 genes in total.
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Figure 10: DGC-SVM-PT with w = 1 ﬁnal model: selected PD genes (UBB, UBE1,
PARK2, CASP3, SNCA, and CASP9) in red; missed PD genes (APAF1, CYCS,
GPR37, SEPT5, SNCAIP, and TH) in green; other selected genes in yellow; unse-
lected genes in white; 181 genes in total.
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